Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

J&J's Simponi Helps Colitis Patients In Clinical Trial

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/21/2012 | 08:45pm CET
   By Peter Loftus 
   Of  
 

Johnson & Johnson (>> Johnson & Johnson) said its drug Simponi improved symptoms in a majority of patients with an inflammatory-bowel disease in a new clinical trial.

The results, released at a medical conference Monday, could support expansion of the approved uses of Simponi to include treating the bowel condition, known as ulcerative colitis, which J&J estimates affects about 700,000 people in the U.S.

Simponi, which was introduced in 2009, is currently approved to treat signs and symptoms of moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.

Simponi is known as an anti-tumor necrosis factor, or anti-TNF, a category that also includes J&J's older drug, Remicade, which is already approved to treat ulcerative colitis. Simponi can be self-administered by patients as an injection, while Remicade requires intravenous infusion by a health-care provider.

J&J recorded $410 million in Simponi sales for 2011; Merck & Co. (MRK), which markets the drug in certain countries outside the U.S., recorded $264 million in Simponi sales for 2011.

J&J tested Simponi in a late-stage clinical trial of more than 770 patients with moderately to severely active ulcerative colitis who had failed to respond to or tolerate certain other treatments.

Some patients received Simponi--at two different dose levels--and some received a placebo, and researchers tracked how many experienced a clinical response at six weeks after the start of treatment. Clinical response included improvements in various symptoms of ulcerative colitis such as diarrhea.

According to J&J, 51.8% and 55% of patients in the two Simponi groups, respectively, achieved a clinical response at week 6, versus 29.7% of placebo patients. The results were presented Monday at the Digestive Disease Week medical meeting in San Diego.

In a secondary measure in the trial, roughly 18.7% and 17.8% of patients in the Simponi groups had clinical remission, versus 6.3% in placebo patients.

The rates of adverse events were comparable among the Simponi and placebo groups, and J&J said the safety of Simponi in the colitis study was consistent with the drug's safety profile in the diseases for which it's already approved.

As a class of drugs, Simponi and other anti-TNFs are associated with increased risk of infections and certain forms of cancer such as lymphoma.

The data suggest Simponi could be a new treatment option for ulcerative colitis patients who don't respond to other drugs, or who prefer the convenience of a subcutaneous injection, said William Sandborn, chief of the division of gastroenterology at the University of California, San Diego, and lead investigator of the J&J-funded study.

J&J also has studied Simponi over a longer treatment duration in colitis patients, and results are expected later this year.

J&J plans to apply for U.S. and European regulatory approval of Simponi as a treatment for ulcerative colitis this year, said J&J spokesman Brian Kenney.

Abbott Laboratories (>> Abbott Laboratories) also has applied for regulatory approval of its anti-inflammatory drug, Humira, as a treatment for ulcerative colitis. European regulators have approved the new indication.

Last year, the FDA declined to approve J&J's requests to market Simponi's ability to inhibit progression of structural damage in both rheumatoid arthritis and psoriatic arthritis.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stocks mentioned in the article : Johnson & Johnson, Abbott Laboratories
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02:39p JOHNSON & JOHNSON : FDA Mini-Sentinel Assessment Confirms Safety and Effectivene..
01/12 WPP Buys London-based Mash Strategy
01/11 JOHNSON & JOHNSON : Dr. Paul Janssen Award for Biomedical Research Issues 2018 C..
01/11 JOHNSON & JOHNSON : Ohio Takes Steps Toward Resolution of Opioid Litigation
01/11 JOHNSON & JOHNSON : Ohio in Talks to Settle Opioid Suit, State Attorney General ..
01/11 JOHNSON & JOHNSON : Investigators at Johnson & Johnson Report Findings in Staphy..
01/11 JOHNSON & JOHNSON : Innovation Champions Leading Edge Science with 15 New Collab..
01/11 JOHNSON & JOHNSON : Bayer and J&J successfully reverse $28 million Xarelto court..
01/10 Bayer, J&J win reversal of US$28 million verdict in Xarelto lawsuit
01/10 BAYER : J&J win reversal of $28 million verdict in Xarelto lawsuit
More news
News from SeekingAlpha
11:35a FDA launches new program to boost transparency of clinical data used to suppo..
08:54a 2018 STRATEGIC OUTLOOK : Will Fortune Favor The Bold In Biotech?
07:01a Novartis' Cosentyx beats Janssen's Stelara in head-to-head psoriasis study
01/15 My Dividend Growth Portfolio - Q4 2017 Summary
01/15 ROAD TO FINANCIAL INDEPENDENCE : My December 88-Stock Portfolio Review
Financials ($)
Sales 2017 76 331 M
EBIT 2017 23 238 M
Net income 2017 16 391 M
Debt 2017 16 824 M
Yield 2017 2,30%
P/E ratio 2017 24,52
P/E ratio 2018 20,34
EV / Sales 2017 5,35x
EV / Sales 2018 4,95x
Capitalization 392 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 148 $
Spread / Average Target 1,3%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON4.32%391 587
NOVARTIS1.80%225 838
ROCHE HOLDING LTD.-0.28%218 350
PFIZER0.88%217 804
MERCK AND COMPANY4.25%159 987
AMGEN6.41%134 322